Amneal completes acquisition of Kashiv BioSciences

Reuters2026/08/10 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amneal completed its acquisition of Kashiv BioSciences, adding end-to-end biosimilar R&D, manufacturing, and commercialization capabilities.
The deal creates a fully integrated biosimilars platform, positioning biosimilars as a long-term growth pillar within Amneal’s Affordable Medicines business.
The combined business targets an expected surge in biologic loss of exclusivity, citing more than $300 billion of projected global opportunities over the next decade.
Integration work is underway, focused on combining development and manufacturing operations while advancing the biosimilar pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806496) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amneal completes acquisition of Kashiv BioSciences

You may also like

Crypto prices